Shots:
The P-III (U-ACHIEVE)/(U-ACCOMPLISH) and (U-ACHIEVE) evaluating the safety & efficacy of upadacitinib (45mg, qd as induction therapy) & 15/30mg, qd as maintenance therapy vs PBO in patients with active UC
The P-III (ADVANCE), (MOTIVATE) and (FORTIFY) study evaluated risankizumab (600/1200mg as induction therapy) & 180/360 mg as maintenance therapy vs PBO in patients with active CD. In both trials, patients had an inadequate response, lost response, or were intolerant to conventional or biological therapy
In induction & maintenance Studies, the patients treated with upadacitinib achieved an improvement in clinical remission & endoscopic response @8 & 52wks. while on risankizumab @12 & 52wks.
Ref: AbbVie | Image: AbbVie
